Bromoketamine Stats & Data

• Market variability: products sold as “BDCK/bromoketamine” show inconsistent potency and may be adulterated or misidentified; rely on multi‑reagent testing plus lab checking when available; a Morris reagent alone cannot distinguish ketamine analogues and can be misleading.

• Intranasal causticity: many users report notable burn, congestion, and colored discharge with BDCK, suggesting greater nasal irritation than ketamine; use small lines, avoid repeated back‑to‑back bumps, and rinse with sterile saline after sessions.

• Very short plateau → redose pressure: BDCK’s compact peak often drives frequent redosing; set hard limits before starting and space doses by at least 60–120 min to reduce cumulative ataxia and accident risk.

• Bladder/biliary risk (inference from ketamine): chronic ketamine is linked to ulcerative cystitis and occasionally biliary tract injury; BDCK’s structural similarity justifies assuming comparable urological risk until proven otherwise. Hydrate, cap frequency (e.g., reserve to occasional sessions), and stop immediately if urinary urgency, pain, or hematuria emerge; seek medical evaluation.

• IM route harm reduction: avoid injecting non‑sterile powders. If choosing IM despite risks, dissolve in sterile water for injection, pass through a new 0.22 µm sterile filter into a sterile vial/syringe, clean skin, rotate sites, and never share equipment. Discard solutions promptly; if storing short‑term, use bacteriostatic water and maintain sterility.

• Set & setting and safety: dissociatives impair coordination and situational awareness; use in a hazard‑free environment, avoid driving or water/baths, and consider a sober sitter for strong doses.

• Respiratory aspiration risk with co‑depressants: mixing with alcohol/GHB/opioids markedly increases unconsciousness and vomiting risks; place any unconscious person in the recovery position and call emergency services if breathing is slow/irregular.

• Tolerance and spacing: dissociative tolerance builds rapidly and decays over 1–3+ weeks; spacing sessions reduces both dose escalation and urologic risk.

• Potency rough‑cut: BDCK is commonly described as ~0.5–0.7× racemic ketamine by weight intranasally, with a shorter, ‘floaty/warm’ effect profile and less profound dissociation at similar mg doses; variability is high across batches.

• Testing and identification: where available, use professional drug checking (GC‑MS/LC‑MS). Self‑testing has detection limits and may miss low‑level adulterants; interpret negative/ambiguous reagent results cautiously.